Related Experiment Video

Updated: Apr 24, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

8.4K

Arginine-directed glycation and decreased HDL plasma concentration and functionality

L Godfrey1, N Yamada-Fowler1, J Smith2

  • 1Clinical Sciences Research Laboratories, Medical School, University of Warwick, University Hospital, Coventry, UK.

Nutrition & Diabetes
|September 2, 2014
PubMed

Insights

Methylglyoxal modification of high-density lipoprotein (HDL) accelerates its degradation and impairs its function, increasing cardiovascular disease (CVD) risk, especially in type 2 diabetes patients.

Area of Science:

  • Biochemistry
  • Cardiovascular Research
  • Metabolic Disease

Background:

  • Low high-density lipoprotein cholesterol (HDL-C) is a risk factor for cardiovascular disease (CVD).
  • Impaired anti-atherogenic properties of HDL are linked to increased CVD risk.
  • The role of glucose intolerance in HDL modification is unclear.

Purpose of the Study:

  • Quantify HDL modification by methylglyoxal and dicarbonyls in healthy individuals and type 2 diabetes patients.
  • Characterize the structural, functional, and physiological consequences of HDL modification.
  • Predict the impact of HDL modification on high CVD risk groups.

Main Methods:

  • Isolated HDL2 and HDL3 fractions from healthy subjects and type 2 diabetes patients.
  • Quantified HDL modification by methylglyoxal and related dicarbonyl metabolites.
  • Assessed molecular, functional, and physiological characteristics of in vitro glycated HDL.
  • Developed a one-compartment model for HDL plasma clearance.

Main Results:

  • Methylglyoxal-modified HDL increased from 2.6% to 4.5% in type 2 diabetes mellitus (T2DM) patients.
  • Methylglyoxal modification restructured HDL particles, decreasing stability and in vivo plasma half-life.
  • Kinetic modeling predicted and clinical data validated a negative correlation between plasma HDL-C and methylglyoxal-modified HDL.

Conclusions:

  • Methylglyoxal modification of HDL accelerates its degradation and impairs its functionality.
  • This modification likely contributes to increased CVD risk, particularly in high-risk populations.
  • Understanding HDL modification is crucial for managing CVD risk in metabolic diseases.
Abstract

More Related Videos

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

18.6K
The Synthesis of RGD-functionalized Hydrogels as a Tool for Therapeutic Applications09:30

The Synthesis of RGD-functionalized Hydrogels as a Tool for Therapeutic Applications

Published on: October 7, 2016

10.8K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
945
Proteoglycans01:05

Proteoglycans

Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
4.0K
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
24
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
23
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
665